Table 4.
Clinical trials of neoantigen-peptide vaccines.
| Trial No. (Brand Name) | Target | Indication | Format/Route of Administration | Combination Therapy | Status |
| NCT04799431 | Personalized NeoAg | MMR-p Colon Cancer Pancreatic Ductal Cancer |
Peptide + poly-ICLC/subcutaneous | Retifanlimab | Phase 1, Not Yet Recruiting |
| NCT03956056 | Personalized NeoAg + Mesothelin | Pancreatic Cancer | Peptide + poly-ICLC/ subcutaneous | N/A | Phase 1, Recruiting |
| NCT04248569 | DNAJB1- PRKACA fusion |
Fibrolamellar Hepatocellular Carcinoma | Peptide + poly-ICLC | Nivolumab, Ipilimumab |
Phase 1, Recruiting |
| NCT04117087 | Common mutant KRAS | Colorectal Cancer Pancreatic Cancer |
Peptide + poly-ICLC | Nivolumab, Ipilimumab |
Phase 1, Recruiting |
| NCT04749641 | Histone H3.3-K27M mutant |
Diffuse Intrinsic Pontine Glioma | Peptide + poly-ICLC/subcutaneous | N/A | Phase 1, Recruiting |
|
NCT03715985 (NeoPepVac) |
Personalized NeoAg | Melanoma, NSCLC, Bladder, Urothelial Carcinoma, |
Peptide + CAF09b/I.P. + I.M. | N/A | Phase 1, Recruiting |
|
NCT03359239 (PGV-001) |
Personalized NeoAg | Urothelial/Bladder Cancer | Peptide + poly-ICLC | Atezolizumab | Phase 1, Recruiting |
|
NCT02149225 (GAPVAC) |
Personalized NeoAg | Glioblastoma | Peptide + poly-ICLC/not specific | TAA peptide vaccine, GM-CSF |
Phase 1, Completed |
| NeoVax | |||||
| NCT01970358 | Personalized NeoAg | Melanoma | Peptide + poly-ICLC/subcutaneous | N/A | Phase 1, Completed |
| NCT02950766 | Personalized NeoAg | Kidney cancer | Peptide + poly-ICLC/subcutaneous | Nivolumab, Ipilimumab |
Phase 1, Recruiting |
| NCT02287428 | Personalized NeoAg | Glioblastoma | Peptide + poly-ICLC | Pembrolizumab Temozolomide (Both selectively) |
Phase 1, Recruiting |
| NCT03929029 | Personalized NeoAg | Melanoma | Peptide + poly-ICLC + Montanide | Nivolumab Ipilimumab |
Phase 1b, Recruiting |
| NCT0402487 | Personalized NeoAg | Ovarian Cancer | Peptide + poly-ICLC | Nivolumab | Phase 1, Recruiting |
| NCT03219450 | Personalized NeoAg | Lymphocytic Leukemia | Peptide + poly-ICLC | Pembrolizumab Cyclophosphamide (both selectively) |
Phase 1, Recruiting |
| Neo-PV-01 | |||||
| NCT03380871 | Personalized NeoAg | Lung cancer | Peptide + poly-ICLC/subcutaneous | Pembrolizumab Carboplatin Pemetrexed |
Phase 1, Completed |
| NCT02897765 | Personalized NeoAg | Urinary Bladder Cancer Melanoma Lung Cancer |
Peptide + poly-ICLC/subcutaneous | Nivolumab | Phase 1, Completed |
Abbreviations: I.V., intravascular infusion. I.M., intramuscular injection. MMR-p, mismatch repair protein deficiency. NSCLC, non-small-cell lung cancer. poly-ICLC, polyinosinic-polycytidylic acid. TAA, tumor-associated antigens.